This partnership
is personal

Solutions aimed at altering the future of cancer

Genomics in Drug Development

Next-generation sequencing (NGS) enables researchers to better understand the biology that drives cancer predisposition and proliferation. These insights can support the development of targeted therapeutics and multi-analyte tumor analysis. NGS also opens the door for discovery of novel methods to monitor cancer treatment and recurrence.

lllumina brings innovation to cancer drug development by offering comprehensive genomic solutions working in collaboration with leading pharmaceutical providers.

Next-generation sequencing (NGS) has forever changed how we study life, health and disease. Watch the animation to learn more and get inspired to become a part of the journey, accelerate your research and discover more.

Companion Diagnostics Development

As targeted therapies make their way through pharmaceutical pipelines, the need for comprehensive tumor profiling is increasing.

Learn More
NGS for Drug Development

NGS helps drug developers to explore genomic variation. This informs target discovery, validation, and clinical development.

Learn More
Interested in receiving newsletters, case studies, and information on genomics in drug development? Enter your email address.
Conducting Innovative Experiments with NGS
Conducting Innovative Experiments with NGS

Chan Zuckerberg Biohub discuss their mission to conduct innovative experiments and new kinds of collaborations in genomics.

View Video
Methods Guide
Methods Guide

All the information you need, from BeadChips to library preparation to sequencer selection and analysis. Select the best tools for your lab.

Access Guide